Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Millward

Showing results (211-220 of 224) with videos related to

Pageof 23
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 20, 2015
A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesotheliomaA K Nowak, A M Cook, A M McDonnell, et al.
Iscience|September 6, 2021
Podoplanin drives dedifferentiation and amoeboid invasion of melanomaCharlotte M de Winde, Samantha L George, Eva Crosas-Molist, et al.
Scientific Data|May 3, 2024
Time-course RNAseq data of murine AB1 mesothelioma and Renca renal cancer following immune checkpoint therapyWee Loong Chin, Rachael M Zemek, Caitlin M Tilsed, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1996
Phase I study of pharmacologically based dosing of carboplatin with filgrastim support in women with epithelial ovarian cancerM J Lind, S Ghazal-Aswad, L Gumbrell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 6, 2005
Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinomaAnthony T C Chan, Mow-Ming Hsu, Boon C Goh, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 17, 1999
Repetitive high-dose therapy with ifosfamide, thiotepa and paclitaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I studyH M Prince, M J Millward, D Rischin, et al.
Nature Communications|August 19, 2022
Temporally restricted activation of IFNβ signaling underlies response to immune checkpoint therapy in miceRachael M Zemek, Wee Loong Chin, Vanessa S Fear, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|August 29, 2020
Association of Known Melanoma Risk Factors with Primary Melanoma of the Scalp and NeckRenee P Wood, Jane S Heyworth, Nina S McCarthy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 24, 2020
Longitudinal Monitoring of ctDNA in Patients with Melanoma and Brain Metastases Treated with Immune Checkpoint InhibitorsJenny H Lee, Alexander M Menzies, Matteo S Carlino, et al.
Science Translational Medicine|July 19, 2019
Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironmentRachael M Zemek, Emma De Jong, Wee Loong Chin, et al.
Pageof 23

Showing results (211-220 of 224) with videos related to

Sort By:
Pageof 23
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 20, 2015
A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesotheliomaA K Nowak, A M Cook, A M McDonnell, et al.
Iscience|September 6, 2021
Podoplanin drives dedifferentiation and amoeboid invasion of melanomaCharlotte M de Winde, Samantha L George, Eva Crosas-Molist, et al.
Scientific Data|May 3, 2024
Time-course RNAseq data of murine AB1 mesothelioma and Renca renal cancer following immune checkpoint therapyWee Loong Chin, Rachael M Zemek, Caitlin M Tilsed, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1996
Phase I study of pharmacologically based dosing of carboplatin with filgrastim support in women with epithelial ovarian cancerM J Lind, S Ghazal-Aswad, L Gumbrell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 6, 2005
Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinomaAnthony T C Chan, Mow-Ming Hsu, Boon C Goh, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 17, 1999
Repetitive high-dose therapy with ifosfamide, thiotepa and paclitaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I studyH M Prince, M J Millward, D Rischin, et al.
Nature Communications|August 19, 2022
Temporally restricted activation of IFNβ signaling underlies response to immune checkpoint therapy in miceRachael M Zemek, Wee Loong Chin, Vanessa S Fear, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|August 29, 2020
Association of Known Melanoma Risk Factors with Primary Melanoma of the Scalp and NeckRenee P Wood, Jane S Heyworth, Nina S McCarthy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 24, 2020
Longitudinal Monitoring of ctDNA in Patients with Melanoma and Brain Metastases Treated with Immune Checkpoint InhibitorsJenny H Lee, Alexander M Menzies, Matteo S Carlino, et al.
Science Translational Medicine|July 19, 2019
Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironmentRachael M Zemek, Emma De Jong, Wee Loong Chin, et al.
Pageof 23